HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CARCINOMA

Clinical trials for HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CARCINOMA trials appear

Sign up with your email to follow new studies for HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Three-Pronged attack on tough kidney cancers

Disease control Recruiting now

This study is testing a combination of three drugs—bevacizumab, erlotinib, and atezolizumab—to see if they can control or shrink advanced kidney cancers linked to a hereditary condition (HLRCC) or a specific type called papillary renal cell cancer. The trial aims to enroll 65 pat…

Matched conditions: HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CARCINOMA

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 10, 2026 12:54 UTC

HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CARCINOMA

Get alerted when new HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CARCINOMA trials appear

Three-Pronged attack on tough kidney cancers